Compare WRBY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRBY | IMNM |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2021 | 2020 |
| Metric | WRBY | IMNM |
|---|---|---|
| Price | $27.67 | $24.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | $27.10 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 3.8M | 1.7M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.88 | 51.40 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $871,905,000.00 | $6,941,000.00 |
| Revenue This Year | $14.48 | N/A |
| Revenue Next Year | $16.41 | $1,127.34 |
| P/E Ratio | $934.67 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $14.96 | $7.96 |
| 52 Week High | $31.00 | $27.65 |
| Indicator | WRBY | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.28 | 70.06 |
| Support Level | $21.16 | $23.67 |
| Resistance Level | $27.59 | $25.10 |
| Average True Range (ATR) | 1.68 | 1.19 |
| MACD | 0.03 | 0.66 |
| Stochastic Oscillator | 50.96 | 84.40 |
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.